The javascript used on this site for creative design effects is not supported by your browser. Please note that this will not affect access to the content on this web site.
Skip Navigation
H H S Department of Health and Human Services
Health Resources and Services Administration
Blood Cell Transplant

A-Z Index  |  Questions?  |  Order Publications

Glossary for the U.S. Transplant Data by Center Report

Disease Status 

A measure of how the disease responded to treatment before the patient received a bone marrow or umbilical cord blood transplant.The disease status can help predict the likelihood of a better or worse survival outcome after transplantation.

In these reports, disease status is included only for leukemias and lymphomas.

Leukemia Disease Statuses

For chronic myelogenous leukemia (CML):

  • In remission—The disease responded well to treatment. There is no clinical evidence of leukemia.
  • 1st chronic phase—The disease responded well to treatment, with clinical evidence of leukemia still present.
  • 2nd chronic phase or higher and accelerated phase —The disease recurred after responding well to initial treatment or progressed despite treatment.
    • 2nd chronic phase or higher means the disease responded well to additional treatement with clinical evidence of the disease still present.
    • Accelerated phase means the disease is progressing rapidly.
  • Blast phase —The disease is not responding to treatment.
  • Unknown—The disease status was not available.

For acute myleogenous leukemia (AML) or acute lymphoblastic leukemia (ALL):

  • In remission—The disease responded well to treatment. There is no clinical evidence of leukemia.
  • Not in remission—The disease is not responding to treatment. There is still evidence of leukemia.
  • Unknown—The disease status was not available.

Lymphoma Disease Statuses

  • In remission—The disease responded well to treatment. There is no clinical evidence of lymphoma.
  • Not in remission—The disease is not responding to treatment. There is still some evidence of lymphoma.
  • Unknown—The disease status was not available.

Donor Type 

Biological relationship between the patient and the donor who provided the blood-forming cells.

  • Autologous—The patient's own cells were collected.
  • Allogeneic—A volunteer donated bone marrow, peripheral blood, or an umbilical cord blood unit. These cells match the patient’s human leukocyte antigen (HLA) type. Specific allogeneic types include:
    • HLA-matched sibling—The brother or sister who donated cells is the patient's biological sibling.
    • Related donor—The family member who donated cells is related biologically to the patient and is not included in the HLA-match sibling category.
    • Unrelated—The person who donated cells is not related biologically to the patient.

Human Leukocyte Antigen (HLA) 

Proteins on cells that make each person's tissue unique.

HLA typing is used to match patients and donors for a bone marrow or umbilical cord blood transplant. (A person's HLA type is identified by testing a blood sample or swab of cheek cells.)